{"id":59825,"date":"2026-03-18T13:31:40","date_gmt":"2026-03-18T05:31:40","guid":{"rendered":"https:\/\/flcube.com\/?p=59825"},"modified":"2026-03-18T13:31:41","modified_gmt":"2026-03-18T05:31:41","slug":"eli-lilly-rolls-out-usd-299-zepbound-kwikpen-via-lillydirect-self-pay-pricing-for-dual-target-obesity-drug","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59825","title":{"rendered":"Eli Lilly Rolls Out USD 299 Zepbound KwikPen via LillyDirect \u2013 Self\u2011Pay Pricing for Dual\u2011Target Obesity Drug"},"content":{"rendered":"\n<p><strong>Eli Lilly and Company<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>) announced that patients can now access the <strong>single\u2011patient\u2011use Zepbound (tirzepatide) KwikPen<\/strong> through <strong>LillyDirect<\/strong> and US pharmacies at <strong>self\u2011pay prices<\/strong>, with the <strong>2.5 mg starting dose available at USD 299 per month<\/strong> \u2013 a strategic pricing move to expand access beyond insurance\u2011covered populations for the first\u2011in\u2011class GIP\/GLP\u20111 dual\u2011agonist obesity therapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-launch-details\">Product Launch Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Zepbound (tirzepatide) KwikPen \u2013 single\u2011patient\u2011use<\/td><\/tr><tr><td><strong>Dose<\/strong><\/td><td>2.5 mg (starting dose)<\/td><\/tr><tr><td><strong>Pricing<\/strong><\/td><td>USD 299 per month (self\u2011pay)<\/td><\/tr><tr><td><strong>Distribution<\/strong><\/td><td>LillyDirect platform + US pharmacies<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Eli Lilly and Company (NYSE: LLY)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-differentiation\">Drug Profile &amp; Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>Tirzepatide<\/strong> \u2013 first and only <strong>dual GIP\/GLP\u20111 receptor agonist<\/strong> approved for obesity<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Simultaneous activation of <strong>GIP (glucose\u2011dependent insulinotropic polypeptide)<\/strong> and <strong>GLP\u20111 (glucagon\u2011like peptide\u20111)<\/strong> receptors<\/li>\n\n\n\n<li><strong>Therapeutic Effect:<\/strong> Root\u2011cause reduction of excess body weight via appetite suppression and decreased food intake<\/li>\n\n\n\n<li><strong>Competitive Position:<\/strong> Distinct from semaglutide (Wegovy\/Ozempic) GLP\u20111 monotherapy; dual\u2011target mechanism demonstrated superior weight loss outcomes in head\u2011to\u2011head trials<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-lillydirect-platform-architecture\">LillyDirect Platform Architecture<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Function<\/th><th>Strategic Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Disease\u2011Specific Resources<\/strong><\/td><td>Patient education and condition management tools<\/td><td>Reduces clinical burden; improves adherence<\/td><\/tr><tr><td><strong>Independent Healthcare Provider Network<\/strong><\/td><td>Telehealth and in\u2011person prescription channels<\/td><td>Expands prescriber reach beyond traditional endocrinology<\/td><\/tr><tr><td><strong>Pharmacy Integration<\/strong><\/td><td>Convenient fulfillment options<\/td><td>Included in <strong>all major EHR systems nationwide<\/strong> \u2013 seamless workflow integration<\/td><\/tr><tr><td><strong>Prescription Fulfillment<\/strong><\/td><td>Direct\u2011to\u2011patient shipping or pharmacy pickup<\/td><td>Reduces supply chain friction; counters compounded GLP\u20111 competition<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pricing Strategy Significance:<\/strong> USD 299 monthly self\u2011pay price represents ~50% discount to Zepbound&#8217;s list price (~US$600\u2011650\/month), positioning Lilly to capture cash\u2011pay patients displaced by Wegovy shortages and compounded semaglutide regulatory crackdowns; estimated addressable market of 2\u20113 million uninsured\/underinsured obesity patients.<\/li>\n\n\n\n<li><strong>LillyDirect Competitive Moat:<\/strong> Platform integration with all major EHRs (Epic, Cerner, Meditech) creates prescriber workflow lock\u2011in; counters Novo Nordisk&#8217;s Wegovy direct\u2011to\u2011consumer marketing with healthcare\u2011professional\u2011anchored distribution model.<\/li>\n\n\n\n<li><strong>Supply Chain Stabilization:<\/strong> Single\u2011patient\u2011use KwikPen format reduces manufacturing complexity vs. multi\u2011dose pens; supports Lilly&#8217;s commitment to resolving historic tirzepatide shortages through simplified production processes.<\/li>\n\n\n\n<li><strong>Revenue Trajectory:<\/strong> Assuming 500,000 self\u2011pay patients by end\u20112026 at USD 299\/month average, incremental revenue potential of <strong>US$1.8 billion annually<\/strong> \u2013 accretive to Zepbound&#8217;s US$5+ billion 2025 revenue base.<\/li>\n\n\n\n<li><strong>Regulatory Tailwinds:<\/strong> FDA intensified enforcement against compounded GLP\u20111 products (March 2025\u20112026) creates demand vacuum that LillyDirect self\u2011pay pricing directly addresses; potential for further indication expansion (sleep apnea, cardiovascular risk reduction) to sustain pricing power.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding patient uptake projections, revenue expectations, and market share dynamics for Zepbound self\u2011pay access. Actual results may differ due to risks including competitive pricing responses, supply constraints, and payer policy changes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and Company (NYSE: LLY) announced that patients can now access the single\u2011patient\u2011use Zepbound&#8230;<\/p>\n","protected":false},"author":1,"featured_media":59827,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[199,911,86],"class_list":["post-59825","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-eli-lilly","tag-nyse-lly","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly Rolls Out USD 299 Zepbound KwikPen via LillyDirect \u2013 Self\u2011Pay Pricing for Dual\u2011Target Obesity Drug - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly and Company (NYSE: LLY) announced that patients can now access the single\u2011patient\u2011use Zepbound (tirzepatide) KwikPen through LillyDirect and US pharmacies at self\u2011pay prices, with the 2.5 mg starting dose available at USD 299 per month \u2013 a strategic pricing move to expand access beyond insurance\u2011covered populations for the first\u2011in\u2011class GIP\/GLP\u20111 dual\u2011agonist obesity therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59825\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly Rolls Out USD 299 Zepbound KwikPen via LillyDirect \u2013 Self\u2011Pay Pricing for Dual\u2011Target Obesity Drug\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly and Company (NYSE: LLY) announced that patients can now access the single\u2011patient\u2011use Zepbound (tirzepatide) KwikPen through LillyDirect and US pharmacies at self\u2011pay prices, with the 2.5 mg starting dose available at USD 299 per month \u2013 a strategic pricing move to expand access beyond insurance\u2011covered populations for the first\u2011in\u2011class GIP\/GLP\u20111 dual\u2011agonist obesity therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59825\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-18T05:31:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-18T05:31:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1802.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59825#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59825\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly Rolls Out USD 299 Zepbound KwikPen via LillyDirect \u2013 Self\u2011Pay Pricing for Dual\u2011Target Obesity Drug\",\"datePublished\":\"2026-03-18T05:31:40+00:00\",\"dateModified\":\"2026-03-18T05:31:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59825\"},\"wordCount\":462,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59825#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1802.webp\",\"keywords\":[\"Eli Lilly\",\"NYSE: LLY\",\"Obesity\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59825#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59825\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59825\",\"name\":\"Eli Lilly Rolls Out USD 299 Zepbound KwikPen via LillyDirect \u2013 Self\u2011Pay Pricing for Dual\u2011Target Obesity Drug - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59825#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59825#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1802.webp\",\"datePublished\":\"2026-03-18T05:31:40+00:00\",\"dateModified\":\"2026-03-18T05:31:41+00:00\",\"description\":\"Eli Lilly and Company (NYSE: LLY) announced that patients can now access the single\u2011patient\u2011use Zepbound (tirzepatide) KwikPen through LillyDirect and US pharmacies at self\u2011pay prices, with the 2.5 mg starting dose available at USD 299 per month \u2013 a strategic pricing move to expand access beyond insurance\u2011covered populations for the first\u2011in\u2011class GIP\\\/GLP\u20111 dual\u2011agonist obesity therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59825#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59825\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59825#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1802.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1802.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eli Lilly Rolls Out USD 299 Zepbound KwikPen via LillyDirect \u2013 Self\u2011Pay Pricing for Dual\u2011Target Obesity Drug\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59825#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly Rolls Out USD 299 Zepbound KwikPen via LillyDirect \u2013 Self\u2011Pay Pricing for Dual\u2011Target Obesity Drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly Rolls Out USD 299 Zepbound KwikPen via LillyDirect \u2013 Self\u2011Pay Pricing for Dual\u2011Target Obesity Drug - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly and Company (NYSE: LLY) announced that patients can now access the single\u2011patient\u2011use Zepbound (tirzepatide) KwikPen through LillyDirect and US pharmacies at self\u2011pay prices, with the 2.5 mg starting dose available at USD 299 per month \u2013 a strategic pricing move to expand access beyond insurance\u2011covered populations for the first\u2011in\u2011class GIP\/GLP\u20111 dual\u2011agonist obesity therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59825","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly Rolls Out USD 299 Zepbound KwikPen via LillyDirect \u2013 Self\u2011Pay Pricing for Dual\u2011Target Obesity Drug","og_description":"Eli Lilly and Company (NYSE: LLY) announced that patients can now access the single\u2011patient\u2011use Zepbound (tirzepatide) KwikPen through LillyDirect and US pharmacies at self\u2011pay prices, with the 2.5 mg starting dose available at USD 299 per month \u2013 a strategic pricing move to expand access beyond insurance\u2011covered populations for the first\u2011in\u2011class GIP\/GLP\u20111 dual\u2011agonist obesity therapy.","og_url":"https:\/\/flcube.com\/?p=59825","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-18T05:31:40+00:00","article_modified_time":"2026-03-18T05:31:41+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1802.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59825#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59825"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly Rolls Out USD 299 Zepbound KwikPen via LillyDirect \u2013 Self\u2011Pay Pricing for Dual\u2011Target Obesity Drug","datePublished":"2026-03-18T05:31:40+00:00","dateModified":"2026-03-18T05:31:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59825"},"wordCount":462,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=59825#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1802.webp","keywords":["Eli Lilly","NYSE: LLY","Obesity"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59825#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59825","url":"https:\/\/flcube.com\/?p=59825","name":"Eli Lilly Rolls Out USD 299 Zepbound KwikPen via LillyDirect \u2013 Self\u2011Pay Pricing for Dual\u2011Target Obesity Drug - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=59825#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=59825#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1802.webp","datePublished":"2026-03-18T05:31:40+00:00","dateModified":"2026-03-18T05:31:41+00:00","description":"Eli Lilly and Company (NYSE: LLY) announced that patients can now access the single\u2011patient\u2011use Zepbound (tirzepatide) KwikPen through LillyDirect and US pharmacies at self\u2011pay prices, with the 2.5 mg starting dose available at USD 299 per month \u2013 a strategic pricing move to expand access beyond insurance\u2011covered populations for the first\u2011in\u2011class GIP\/GLP\u20111 dual\u2011agonist obesity therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59825#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59825"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=59825#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1802.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1802.webp","width":1080,"height":608,"caption":"Eli Lilly Rolls Out USD 299 Zepbound KwikPen via LillyDirect \u2013 Self\u2011Pay Pricing for Dual\u2011Target Obesity Drug"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59825#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly Rolls Out USD 299 Zepbound KwikPen via LillyDirect \u2013 Self\u2011Pay Pricing for Dual\u2011Target Obesity Drug"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1802.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59825","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59825"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59825\/revisions"}],"predecessor-version":[{"id":59828,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59825\/revisions\/59828"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/59827"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59825"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59825"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59825"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}